| Metric | Value (₹ Cr) | Q1 FY27 | Q2 FY26 |
|---|---|---|---|
| Revenue | 7.8K | 5.4% | 11.1% |
| Total Income | 8.0K | 5.4% | 11.4% |
| Expenditure | 6.4K | 0.2% | 24.3% |
| PBT | 1.6K | 21.7% | 21.3% |
| Net Profit | 1.2K | 18.5% | 22.2% |
| OPM | 26.12% | 3.48pp | 7.10pp |
| NPM | 14.52% | 2.33pp | 6.28pp |
| EPS | 25.27 | 18.4% | 21.9% |
Detailed report is being prepared.
Can Lupin sustain Q1's US momentum into Q2?
After a blockbuster Q1 that beat Street estimates by ~17–31%, the test is whether the US generics surge and India recovery can hold into the September quarter. Street expects 6.4% FY27 revenue growth and is watching for margin expansion and guidance reiteration.
The Setup: Q1 Beat, Now the Test
Lupin's Q1 FY27 was a breakout — revenue of ₹8,276.89 Cr surged 32% YoY and beat Street consensus (₹6,300–7,096 Cr) by a wide margin. EBITDA grew 42.8% YoY to ₹2,580 Cr, lifting margins to 29.59%. The US generics portfolio fired; India sales recovered. Management guided for $1 billion+ US sales in FY27, a milestone threshold. Now comes the September quarter: can the company hold momentum, or will it normalize? The Street's modest 6.4% FY27 revenue growth forecast (₹29.75k Cr) and expectations of 27% EPS upgrade suggest they see durability, but Q2 is the proof point.
~₹8,500 Cr
Mid-point of sustained momentum: ~3–5% sequential from Q1's ₹8,277 Cr
28–30%
Continuation of margin expansion from US mix and operating leverage
+20–25% (est.)
Q1 saw tax normalization drag; normalized run-rate suggests mid-20s growth
$1B+ US sales
Management's full-year anchor; Q2 track will validate or flag headwinds
A strong Q2 print means: revenue ₹8,400–8,600 Cr (hold momentum), EBITDA margin ≥29%, and no guidance downside. Margins staying elevated would signal that US generics mix and India volume recovery are durable, not one-quarter beats. A weak print would see revenue miss ₹8,200 Cr, margin compression below 27%, or guidance caution on US volume or pricing pressure — the latter a Street concern given the stock's valuation ceiling despite the beat.
Tracking vs Guidance: Is FY27 On Plan?
Lupin's FY27 compass: $1 billion US sales (6.4% consolidated revenue growth, ₹29.75k Cr total) and margin expansion. Q1 delivered 32% revenue growth YoY, far ahead of the 6.4% annual plan — a sign of either a strong base or upside optionality. The question: is Q1 the new normal, or does Q2 normalize toward guidance? Two quarters into FY27, if Q2 also prints ₹8,400+ Cr, management may be forced to upgrade full-year revenue guidance. If Q2 slows to ₹8,000 Cr or below, Street expectations of 6.4% growth still hold, but it signals Q1 was a peak. The margin story is equally critical: can Lupin hold 28–30% EBITDA margins? Q1's 29.6% was strong; sustained levels would validate pricing power in the US and volume growth in India.
What the Street Says
Since Q1: Filings & Event Scan
1 · US FDA Goa Facility Inspection (Oct 19–23, 2026)
One Form-483 observation (minor non-conformance). No production halt flagged. Routine remediation expected; no product impact signaled. Context: standard inspection hygiene; low material risk.
2 · Brian Savage Appointed President & Chief Legal Officer (Oct 22, 2026)
New senior hire based in New Jersey, overseeing legal, compliance, and IP. Signals US operational buildup. Positive for $1B US sales push; no negative signal for financials.
3 · Multiple US FDA Approvals (Aug–Oct 2026)
Phytonadione injectable, Apixaban oral suspension, Modafinil, Pitolisant, Sodium Zirconium Cyclosilicate, Diazepam injection. Adds to pipeline depth; suggests steady inorganic growth via new ANDA launches. Positive for FY27 US revenue trajectory.
4 · India Product Launch: Formoflo-G® Triple Combo MDI (Oct 6, 2026)
World's first fixed-dose triple-combination metered-dose inhaler for COPD. India market innovation play; differentiates Lupin in respiratory (growth segment). Positive for India volumes in H2.
5 · MPPI Subsidiary Becomes Wholly Owned (Oct 1, 2026)
Multicare Pharmaceuticals Philippines buyback completed. Consolidates overseas footprint. Routine corporate action; no earnings impact expected.
6 · Ownership Shift: FII +0.71pp, DII –0.67pp (Q1 FY27 vs Q4 FY26)
Marginal foreign inflow despite strong earnings. Suggests institutional caution on valuation despite fundamentals. Stock supply/demand in balance.
What to Watch on Result Day (November 3)
1 · US Generics Growth: Can it hold 20%+ YoY?
Q1 was strong; Q2 will signal if this is sustained or peaking. USD terms are critical — any FX drag on INR reporting should be called out. Management guidance for $1B+ FY27 sales hinges on this segment.
2 · India Volume vs Price: Mix in domestic recovery
India segment recovered in Q1 after weakness; Q2 confirms the trend or flags normalization. Monitor per-unit growth and pricing trends — a volume-led vs price-driven growth story signals different durability.
3 · EBITDA Margin Sustainability: 28%+ or pullback?
Q1 hit 29.6%; this quarter will show if it's structural (US mix, operating leverage) or beneficiary of one-time items. Any margin compression below 27% is a red flag. Management's commentary on cost inflation and mix is key.
Lupin enters Q2 earnings on the back of a landmark Q1 beat, but the Street's modest 6.4% FY27 growth forecast and muted stock price reaction (down 22.8% from ATH despite earnings surprise) suggest institutional caution on durability and valuation. The company has delivered on the US growth and India recovery narrative, but Q2 will test whether momentum holds or reverts to guidance. Watch the absolute revenue level (₹8,200–8,600 Cr), margin sustainability (28%+), and any commentary on full-year guidance. Strength here could re-rate the stock; a miss will validate the valuation ceiling thesis.
Key items: US generics YoY growth, India segment mix (volume vs price), EBITDA margin structural vs cyclical, and any FY27 guidance reiteration or raise.